Johnson & Johnson

Q3 2026
Speakers

Oct 13, 2026 · 64 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Good morning and welcome to Johnson ⁇ Johnson's third quarter 2026 earnings conference call. All participants will be in the listen-only mode until the question and answer session of the conference. This call is being recorded. If anyone has any objections, you may disconnect at this time. If you've experienced any technical difficulties during the conference, you may press star zero to reach the operator. ?

I
will now turn the conference call over to Johnson ⁇ Johnson. You may begin.

Passages & reports (4)
  • Good morning and welcome to Johnson ⁇ Johnson's third quarter 2026 earnings conference c…
  • the conference, you may press star zero to reach the operator.
  • I
  • will now turn the conference call over to Johnson ⁇ Johnson. You may begin.

Speaker 1

Unverified voice label

Hello everyone. This is Ryan Kors, Vice President of Investor Relations for Johnson Johnson. Welcome to our company's review of business results for the third quarter of 2026 and our financial outlook for the full year. First, a few logistics. As a reminder, today's presentation and associated schedules are available on the Investor Relations section of the Johnson Johnson website at investor.jnj.com. Please note that this presentation contains forward-looking statements regarding, among other things, the company's future operating and financial performance, market position, and business strategy. ?

You
are cautioned not to rely on these forward-looking statements, which are based on the current expectations of future events using the information available as of the date of this recording. They are subject to certain risks and uncertainties that may cause the company's actual results to differ materially from those projected. ?The description of these risks, uncertainties, and other factors can be found in our SEC filings, including our 2025 Form 10K, which is available at investor.jnj.com and on the SEC's website.

Additionally, several of the products and compounds discussed today are being developed in collaboration with strategic partners or
licensed from other companies. This slide acknowledges those relationships. Moving to today's agenda, Joaquin DeWato, our chairman and CEO, will discuss our business performance and growth drivers. I will then review the third quarter sales and PL results. Joe Walk, our CFO, will then close by sharing an overview of our capital allocation priorities and updated guidance for 2026.

Tom Cavanaugh, Executive Vice President, Worldwide Chairman Innovative Medicine, John Reid, Executive Vice President Innovative Medicine Research and Development, and Tim Schmid, Executive Vice President Worldwide Chairman MedTech, will be joining us for QA.
?To ensure we provide enough time to address your questions, we anticipate the webcast will last approximately 60 minutes. With that, I will now turn the call over to Joaquin. Thank you, Ryan, and good morning, everyone.

Our strong performance in the third quarter reinforces our confidence in twenty twenty six as a year of
accelerated growth and impact for Johnson and Johnson. In Q three, we reported operational sales growth of six percent, ahead of analyst consensus, and increased sequential growth compared to the second quarter. With six strategic focused areas oncology, immunology, neuroscience, cardiovascular surgery and vision, we are leading in areas of higher media where innovation can make the greatest difference for patients.

Our powerful combination of innovative medicine and medtech expertise strengthens our
competitiveness. Twenty-nine of our products and platforms now generate at least one billion dollars in annual sales. Our marketed portfolio continues to perform, our launches are gaining significant traction, and we are advancing our new product pipeline that will sustain our growth into the next decade. With sales in the quarter of more than $25 billion, we are on track to meet our guidance and exceed $100 billion in annual revenue for the first time in our company's

Passages & reports (14)
  • Hello everyone. This is Ryan Kors, Vice President of Investor Relations for Johnson Johnso…
  • Relations section of the Johnson Johnson website at investor.jnj.com. Please note that thi…
  • You
  • are cautioned not to rely on these forward-looking statements, which are based on the curr…
  • The
  • description of these risks, uncertainties, and other factors can be found in our SEC filin…
  • licensed from other companies. This slide acknowledges those relationships. Moving to toda…
  • overview of our capital allocation priorities and updated guidance for 2026. Tom Cavanaugh…
  • To
  • ensure we provide enough time to address your questions, we anticipate the webcast will la…
  • accelerated growth and impact for Johnson and Johnson. In Q three, we reported operational…
  • oncology, immunology, neuroscience, cardiovascular surgery and vision, we are leading in a…
  • competitiveness. Twenty-nine of our products and platforms now generate at least one billi…
  • sustain our growth into the next decade. With sales in the quarter of more than $25 billio…

Speaker 2

Unverified voice label

and forty year history. As we advance our differentiated portfolio and pipeline, we have a clear path to double digit growth by the end of the decade. In innovative medicine, we delivered

Passages & reports (1)
  • and forty year history. As we advance our differentiated portfolio and pipeline, we have a…

Speaker 1

operational sales

Passages & reports (1)
  • operational sales

Speaker 2

growth of seven point nine percent, with eight brands growing double digits. Let's start with oncology. We are making progress to redefine cancer care from treatment to cure. In the third quarter our oncology business grew approximately 17%. Our multiple myeloma portfolio and pipeline are unmatched, with 80% of patients receiving a Johnson Johnson therapy as part of their treatment journey. And we continue to strengthen the body of evidence supporting our recently launched multiple myeloma therapies and combination regimens.

New phase three results announced in July demonstrated that the combination of the bailey plastalvee reduced the risk of disease progression or death by 89% as early as the second line of treatment. In solid
tumors, sales of ribreband increased by 64%, reflecting its strength in lung cancer. And by the end of the year, we expect to receive US FDA approval for Ribreband FASPRO in advanced head and neck cancer, a disease with significant methods. ?

In
bladder cancer in LEXO has rapidly emerged as a market leader for new patient share just one year after its launch. Nearly one in three eligible patients started on an ILEXO regimen in the third quarter, demonstrating its growing role in transforming care in high-risk non muscle invasive disease. During the quarter, we also invested to bolster our oncology pipeline. We completed our acquisition of Firefly Bio, adding a promising new degraded antibody conjugate platform that targets drivers of difficult to treat cancers, including CARAS.

Our ambition is to become the number one oncology company by two thousand thirty with sales projected to exceed fifty billion dollars. Turning to immunology, we are building on
our twenty five year legacy to drive industry leading innovation for patients. Tremfaia delivered exceptional sales growth of sixty eight percent in the quarter, reflecting strong momentum across its indications.

Passages & reports (10)
  • growth of seven point nine percent, with eight brands growing double digits. Let's start w…
  • multiple myeloma portfolio and pipeline are unmatched, with 80% of patients receiving a Jo…
  • and combination regimens. New phase three results announced in July demonstrated that the …
  • tumors, sales of ribreband increased by 64%, reflecting its strength in lung cancer. And b…
  • methods.
  • In
  • bladder cancer in LEXO has rapidly emerged as a market leader for new patient share just o…
  • transforming care in high-risk non muscle invasive disease. During the quarter, we also in…
  • that targets drivers of difficult to treat cancers, including CARAS. Our ambition is to be…
  • our twenty five year legacy to drive industry leading innovation for patients. Tremfaia de…

Speaker 2

Utubrand share in Crohn's disease, Alcerative colitis, and psoriatic arthritis. And we continue to generate evidence that reinforces Tremfaia's clinical differentiation. Based on the landmark STAR study, Tremphaya is the first and only IL-23 inhibitor to demonstrate positive outcomes in axial disease clinical trials, including significant improvement in spinal pain, stiffness and inflammation in patients with psoriatic arthritis. This momentum reinforces our conviction in Tremphaya as a foundational medicine in inflammatory bowel and psoriatic diseases, and our belief that it can grow into a ten billion dollar plus franchise.

Passages & reports (3)
  • Utubrand share in Crohn's disease, Alcerative colitis, and psoriatic arthritis. And we con…
  • inhibitor to demonstrate positive outcomes in axial disease clinical trials, including sig…
  • foundational medicine in inflammatory bowel and psoriatic diseases, and our belief that it…

Speaker 2

More than twenty thousand patients have initiated therapy through nearly 9,000 prescribers since ICOTID's launch in the US. We continue to make strong progress on commercial access with Icotide now broadly covered across all national plants. Also this quarter IMABI was approved as the first advanced treatment specifically for worm autoimmune hemolytic anemia, a rare, life threatening disease that causes severe anemia and fatigue. This new indication builds on imabis momentum in generalized myasthenia gravis and reflects its broad potential across auto antibody diseases.

And we continue to pursue next generation therapies. In July, we announced a collaboration with Sale Biomedicines to advance in VivoCARTI approaches
for immune-mediated mediated diseases. Next, in neuroscience, we aim to transform the future of brain health by addressing complex nervous system disorders. Today we are the definitive leader in neuropsychiatry. Caplita reached $1 billion in year to date sales, making it our $29 billion platform.

Driven by strong uptake as an adjunctive treatment for major depressive disorder. Caplita is now the fastest growing oral branded therapy in this space. And
last month we presented pivotal phase three data that show caplita significantly and rapidly improved symptoms of bipolar mania. Spravato also delivered impressive growth of 36% this quarter, reflecting strong demand in treatment resistant depression. Now let's turn to MedTech, where we deliver Q3 operational sales growth of 2.5%.

While we fell short of our expectations for the segment, our conviction in our future direction has not changed.

Passages & reports (7)
  • More than twenty thousand patients have initiated therapy through nearly 9,000 prescribers…
  • Also this quarter IMABI was approved as the first advanced treatment specifically for worm…
  • generalized myasthenia gravis and reflects its broad potential across auto antibody diseas…
  • for immune-mediated mediated diseases. Next, in neuroscience, we aim to transform the futu…
  • in year to date sales, making it our $29 billion platform. Driven by strong uptake as an a…
  • last month we presented pivotal phase three data that show caplita significantly and rapid…
  • treatment resistant depression. Now let's turn to MedTech, where we deliver Q3 operational…

Starting with cardiovascular, we continue to invest in heart recovery, circulatory restoration, and heart rhythm disorders to address the leading global cause of death. This was another strong quarter for Shockwave, our circulatory restoration business, which grew 17%. The ongoing global launch of Shockwave C2 Aero continues to broaden the reach of our intravascular lithotherpsy platforms. VARIPuls, our pushed field ablation platform, reached a major milestone this quarter with more than a hundred thousand AV patients treated worldwide.

BARIPULSPRO, which delivers five times faster ablation speed, has been very well received in Europe, where it is driving double digit growth. And just last week we received approval for BARIPuls Pro in Japan.

Passages & reports (3)
  • Starting with cardiovascular, we continue to invest in heart recovery, circulatory restora…
  • 17%. The ongoing global launch of Shockwave C2 Aero continues to broaden the reach of our …
  • AV patients treated worldwide. BARIPULSPRO, which delivers five times faster ablation spee…

With increasing clinical experience we are seeing differentiated benefits from BARIPuls. In a recent retrospective analysis, BariPulse demonstrated a sixty eight percent lower risk of adverse cardiac events compared to a competing post field ablation platform. And in hard recovery, while physician selectivity continued to affect the biomed performance, we remain confident in the technology and focused on supporting appropriate patient selection. In surgery, we are poised to shape the next era of care through robotics, digital innovation and advanced instrumentation.

In July, the US FDA granted the Nova Authorization for Ottawa, the world's first stable integrated soft tissue robotic system. This is one of the most
significant Metek innovations we will bring to market this decade. Ottawa's unique architecture, automated features and next generation robotic instruments help address surgeon needs for operating room space and better surgical workflows. Its connection to our open digital ecosystem polyphonic turns procedure data into actionable insights for clinicians.

We already signed our first commercial customer for Ottawa and we are progressing our development programme. Our investigational device
exemption trial is already underway in inguinal hernia repair with future plans for indication expansion into urology and gynecology. Finally, in vision, we are advancing lifelong eye health to bring better sight to more than 40 million people each year. The recent US launch of TechnisPurcy further strengthened our portfolio of intraocular lenses.

During the quarter, Technispu PureC and Technis Odyssey surpassed one million implants worldwide,
reflecting continued surgeon adoption and our leadership in personalised vision solutions. We also received C marking for Acquiview OACs max two week reusable lenses, expanding our Acquiew portfolio in Europe.

Passages & reports (8)
  • With increasing clinical experience we are seeing differentiated benefits from BARIPuls. I…
  • ablation platform. And in hard recovery, while physician selectivity continued to affect t…
  • of care through robotics, digital innovation and advanced instrumentation. In July, the US…
  • significant Metek innovations we will bring to market this decade. Ottawa's unique archite…
  • connection to our open digital ecosystem polyphonic turns procedure data into actionable i…
  • exemption trial is already underway in inguinal hernia repair with future plans for indica…
  • more than 40 million people each year. The recent US launch of TechnisPurcy further streng…
  • reflecting continued surgeon adoption and our leadership in personalised vision solutions.…

Overall, this quarter's strong results demonstrate the impact of the choices we have made to build a foundation for durable growth. We sharpened our portfolio to focus on innovation with the greatest potential to change lives. We proved our ability to grow through a significant loss of exclusivity. Our strategic investments in high growth areas are delivering results, and our innovation engine continues to drive breakthroughs for patients.

That is why we have the confidence to say that we will finish twenty twenty six strong
and that twenty twenty seven will be an even better year for Johnson and Johnson. I will now turn the call back over to Ryan.

Passages & reports (3)
  • Overall, this quarter's strong results demonstrate the impact of the choices we have made …
  • a significant loss of exclusivity. Our strategic investments in high growth areas are deli…
  • and that twenty twenty seven will be an even better year for Johnson and Johnson. I will n…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 1

you,

Passages & reports (1)
  • you,

Speaker 2

Joaquin.

Passages & reports (1)
  • Joaquin.

Speaker 1

Moving to our financial results.

Passages & reports (1)
  • Moving to our financial results.

Speaker 1

Starting with Q three twenty twenty six sales results. Worldwide sales were twenty five point four billion dollars for the quarter, increasing six percent. Growth in the US was nine point one percent and one point eight percent outside the US. Acquisitions and divestitures had a net negative impact on worldwide growth of ten basis points. Now turning to earnings. ?For the quarter, net earnings were two hundred and ten million dollars and diluted earnings per share were nine cents versus two dollars and twelve cents a year ago.

Results in the quarter were impacted by the proposed talc litigation resolution, as well as expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration, amounting to
approximately $7 billion. Adjusted net earnings for the quarter were $6.3 billion, and adjusted diluted earnings per share were $2.59, representing a decrease of 6.8% and 7.5% respectively, compared to the third quarter of 2025. Adjusted earnings in the quarter were also impacted by expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration.

I will now comment on business sales results in the quarter, focusing on the six key areas where meaningful innovation and strong commercial execution are driving our performance and fueling long-term growth. Beginning with innovative medicine, where our
financial results reflect the depth of our expertise in innovation in areas of high unmet need across oncology, immunology, and neuroscience. Worldwide sales of $16.8 billion dollars increased seven point nine percent, which underscores the continued strength of our key brands and new launches.

Growth in the U.S. was eleven point one
percent and three percent outside the U.S. Divestitures had a negative impact of ten basis points on worldwide growth. In oncology, starting with multiple myeloma, DARZLEC's growth was fifteen point six percent, primarily driven by strong share gains of five points across all lines of therapy, with ten points in the frontline setting, as well as continued market growth, partially offset by OUS pricing headwinds.

Pervicti achieved growth of 35.2%, driven by share gains across earlier lines of therapy and continued site expansion. TechVailey growth was 77.3%, driven by launch uptake
and share gains across earlier lines of therapy following last quarter's approval in the U.S. ?for TechVailey plus Starzilex FastPro with U.S. growth greater than 100%. Talve growth was forty-two point one percent, driven by shear gains due to increased depth of prescribing in the community setting.

In lung cancer, ribant plus last glues delivered growth of sixty-three point five percent, with strong share gains in
the first and second lines driven by continued launch uptake in all regions, along with rapid uptake in Ribovant FastPro. ?In prostate cancer, Erlita delivered growth of 9.4%, with continued shear gains and market growth, partially offset by unfavorable patient mix. Within immunology, Trimfaya delivered impressive growth of 68.2%, driven by continued momentum from the IBD launch, with four points of share growth in both all sort of colitis and Crohn's disease, alongside continued market growth.

Stellara declined 54%, which reflects continued competitive pressures from biosimilars and the ongoing shift towards novel classes. Growth in other immunology is driven by AMAVA and Icottide launch uptake in the US.
?In neuroscience, Spravato grew 36%, driven by continued share gains reflecting strong physician adoption and increased patient demand. Keplita showed significant growth of 66.1%, driven by strong continued launch momentum and adjunctive major depressive disorder and continued demand increases across bipolar disorder and schizophrenia. ?

Now
moving to MedTech. Worldwide sales of $8.6 billion increased 2.5%, with growth of 4.8% in the US and 0.1% outside the US. Overall cardiovascular grew 4.1%, including 20 basis points related to acquisitions. Electrophysiology delivered growth of 4.4%, driven by procedure expansion, commercial execution, and new product performance, partially offset by competitive PFA pressures which were more pronounced in ASPAC this quarter, as well as the lapping of prior year OUS inventory dynamics.

ABIMED saw a decline of 1.5% due to lower
patient volume. ?There are encouraging signals in the U.S. performance with improvement in the quarter, supported by acute myocardial infarction, cardiogenic shock, and impella 5.5 continuing to gain adoption. Shockwave grew double digits at 17.2%, driven by continued adoption of coronary and peripheral products as well as new product launches, and the reimbursement in the office based lab setting within the U.S.

Surgery saw a decline of 1%, including a negative impact of approximately 30 basis points from divestitures.
?The decline is more notably driven by ongoing expansion of VBP in China, surgery transformation program outcomes across the portfolio, and Middle East disruption which impacted tender timing and ordering patterns. ?The decline was partially offset by portfolio strength, driven by recent innovations such as Ethicon 4000 and Dualto, as well as commercial execution and biosurgery. ?

In
Vision, growth was 5.1%, driven by premium innovation, strong execution, and global reach. Contact lenses and other products grew 4.3%, driven by strong performance in the Accuview OASIS one-day family of products, further solidifying our leadership position, partially offset by U.S. inventory dynamics. Surgical Vision delivered growth of 7.1%, driven by new product innovations, robust demand for premium IOLs, and strong commercial execution, partially offset by market specific factors such as disruptions in the Middle East.

Orthopedics growth for the quarter was three point four percent, primarily driven
by new product launches such as Volt and Trauma and Emphasis and HIPS, including strong commercial execution and vellus pull through and knees. ?Now turning to our consolidated statement of earnings for the third quarter of twenty twenty six. I'd like to highlight a few noteworthy items that have changed compared to the same quarter of last year.

Cost of goods sold deleveraged by 150 basis points driven by unfavorable product sales mix and increased intangible asset amortization expense
in the innovative medicine segment for intracellular, partially offset by the impact of tariff recoveries in the med tech business. Selling, marketing, and administrative expenses were flat as a percent of sales, reflecting consistent commercial investments in the innovative medicine business. We continue to invest strategically in research and development, deploying approximately 4.7 billion or 18.3% of sales, which includes $1 billion related to the acquisition of Firefly Bio. ?

In
process, research and development impairment costs of $339 million in the quarter is related to the write-off of Precardia, a non-core asset acquired as part of the broader ABIMED transaction. Other income and expense with a net expense of $5.8 billion as compared to $478 million of income in the third quarter of 2025, with the change primarily driven by the proposed talc litigation resolution and orthopedic separation related costs.

The tax rate was a small net benefit in the quarter, primarily related to the positive tax effect associated with the accrual for the proposed TAC litigation resolution. More information can be found in our upcoming 10 Q for
changes in taxes. Lastly, I'll direct your attention to the box section of the slide where we have also provided our income before tax, net earnings, and earnings per share adjusted to exclude the impact of intangible amortization expense and special items. ?

Now
let's look at the adjusted income before tax by segment for the quarter. Innovative medicine margin declined from 44.3% to 35.4%, primarily due to acquired in process research and development expense of approximately $1 billion related to the acquisition of Firefly Bio, transaction cost for sale biomedicine, and unfavorable product sales mix and cost of products sold. MedTech margin increased from 21% to 22.9%, driven by the impact of tariff recoveries, partially offset by increased strategic investments in commercial capabilities.

As a result, adjusted income before tax for the
enterprise, as a percentage of sales, decreased from 35.2% to 30.2%. This concludes the sales and earnings portion of the call, and I will now turn the call over to Joe.

Passages & reports (46)
  • Starting with Q three twenty twenty six sales results. Worldwide sales were twenty five po…
  • points. Now turning to earnings.
  • For
  • the quarter, net earnings were two hundred and ten million dollars and diluted earnings pe…
  • approximately $7 billion. Adjusted net earnings for the quarter were $6.3 billion, and adj…
  • expenses associated with the Firefly Biotransaction and Sale Biomedicines collaboration. I…
  • financial results reflect the depth of our expertise in innovation in areas of high unmet …
  • percent and three percent outside the U.S. Divestitures had a negative impact of ten basis…
  • setting, as well as continued market growth, partially offset by OUS pricing headwinds. Pe…
  • and share gains across earlier lines of therapy following last quarter's approval in the U…
  • for
  • TechVailey plus Starzilex FastPro with U.S. growth greater than 100%. Talve growth was for…
  • the first and second lines driven by continued launch uptake in all regions, along with ra…
  • In
  • prostate cancer, Erlita delivered growth of 9.4%, with continued shear gains and market gr…
  • colitis and Crohn's disease, alongside continued market growth. Stellara declined 54%, whi…
  • In
  • neuroscience, Spravato grew 36%, driven by continued share gains reflecting strong physici…
  • disorder and schizophrenia.
  • Now
  • moving to MedTech. Worldwide sales of $8.6 billion increased 2.5%, with growth of 4.8% in …
  • growth of 4.4%, driven by procedure expansion, commercial execution, and new product perfo…
  • patient volume.
  • There
  • are encouraging signals in the U.S. performance with improvement in the quarter, supported…
  • launches, and the reimbursement in the office based lab setting within the U.S. Surgery sa…
  • The
  • decline is more notably driven by ongoing expansion of VBP in China, surgery transformatio…
  • The
  • decline was partially offset by portfolio strength, driven by recent innovations such as E…
  • In
  • Vision, growth was 5.1%, driven by premium innovation, strong execution, and global reach.…
  • dynamics. Surgical Vision delivered growth of 7.1%, driven by new product innovations, rob…
  • by new product launches such as Volt and Trauma and Emphasis and HIPS, including strong co…
  • Now
  • turning to our consolidated statement of earnings for the third quarter of twenty twenty s…
  • in the innovative medicine segment for intracellular, partially offset by the impact of ta…
  • deploying approximately 4.7 billion or 18.3% of sales, which includes $1 billion related t…
  • In
  • process, research and development impairment costs of $339 million in the quarter is relat…
  • with the change primarily driven by the proposed talc litigation resolution and orthopedic…
  • changes in taxes. Lastly, I'll direct your attention to the box section of the slide where…
  • Now
  • let's look at the adjusted income before tax by segment for the quarter. Innovative medici…
  • biomedicine, and unfavorable product sales mix and cost of products sold. MedTech margin i…
  • enterprise, as a percentage of sales, decreased from 35.2% to 30.2%. This concludes the sa…

Speaker 2

Thanks, Ryan. Hello, everyone, and thank you for joining us today. ?As you heard from Joaquin and Ryan, our third-quarter results were driven by the strength of our our innovative medicine business.

Passages & reports (3)
  • Thanks, Ryan. Hello, everyone, and thank you for joining us today.
  • As
  • you heard from Joaquin and Ryan, our third-quarter results were driven by the strength of …

Speaker 1

This performance more than offset headwinds in certain areas of medtech, enabling us to exceed expectations on both the top and bottom line while continuing to invest in our pipeline and future growth. ?We are clear on where medtech performance needs to improve, specifically cardiovascular and surgery outside the U.S., and are taking action to strengthen results. While disappointing, the underlying fundamentals of the med tech business remain strong, supporting our confidence in the long term for that business.

Across Johnson Johnson, the drivers
underpinning our outlook remain firmly in place. As a result, we are raising our guidance for 2026 versus our most recent update in July. The depth of our portfolio, momentum from new product launches, and upcoming pipeline catalysts further reinforce our conviction in achieving double digit growth by the end of this decade with sustainable growth beyond. Turning to financial metrics and

Passages & reports (5)
  • This performance more than offset headwinds in certain areas of medtech, enabling us to ex…
  • We
  • are clear on where medtech performance needs to improve, specifically cardiovascular and s…
  • underpinning our outlook remain firmly in place. As a result, we are raising our guidance …
  • with sustainable growth beyond. Turning to financial metrics and

Speaker 2

our cash position, we ended the third quarter with approximately $17 billion of cash

Passages & reports (1)
  • our cash position, we ended the third quarter with approximately $17 billion of cash

Speaker 1

and marketable securities

Passages & reports (1)
  • and marketable securities

Speaker 2

and approximately $45 billion of debt for a net debt position of approximately $28 billion, generating more than $6 billion in free cash

Passages & reports (1)
  • and approximately $45 billion of debt for a net debt position of approximately $28 billion…

Speaker 1

flow in the

Passages & reports (1)
  • flow in the

Speaker 2

third quarter. We remain confident in our full year free cash flow guidance of approximately $21 billion. During the quarter, we completed the $1 billion acquisition of Firefly Bio, deepening capabilities in oncology with next generation antibody engineering to address complex tumor biology. As Joaquin referenced earlier, we also entered into a collaboration with Sale Biomedicines to advance in vivo CART T therapies for immune-mediated diseases. ?

Our
disciplined approach to capital allocation is principled on

Passages & reports (4)
  • third quarter. We remain confident in our full year free cash flow guidance of approximate…
  • As Joaquin referenced earlier, we also entered into a collaboration with Sale Biomedicines…
  • Our
  • disciplined approach to capital allocation is principled on

Speaker 1

prioritizing investments that support key commercial launches, accelerating future innovation, increasing our annual dividend, and strengthening our pipeline through strategic

Passages & reports (1)
  • prioritizing investments that support key commercial launches, accelerating future innovat…

Speaker 2

value creating inorganic opportunities. ?In July, we announced an agreement

Passages & reports (3)
  • value creating inorganic opportunities.
  • In
  • July, we announced an agreement

Speaker 1

for a

Passages & reports (1)
  • for a

Speaker 2

resolution of the ovarian Talc litigation for $5.5 billion, which is reflected in our third

Passages & reports (1)
  • resolution of the ovarian Talc litigation for $5.5 billion, which is reflected in our thir…

Speaker 1

quarter GAAP

Passages & reports (1)
  • quarter GAAP

Speaker 2

results. The agreement

Passages & reports (1)
  • results. The agreement

Speaker 1

is conditioned upon the express participation ?of at least 95% of the remaining ovarian claims. We are trending to meet the 95% threshold. ?Let me now turn

Passages & reports (5)
  • is conditioned upon the express participation
  • of
  • at least 95% of the remaining ovarian claims. We are trending to meet the 95% threshold.
  • Let
  • me now turn

Speaker 2

to full year

Passages & reports (1)
  • to full year

Speaker 1

2026 guidance.

Passages & reports (1)
  • 2026 guidance.

Speaker 2

As always, our outlook

Passages & reports (1)
  • As always, our outlook

Speaker 1

reflects

Passages & reports (1)
  • reflects

Speaker 2

what we know today regarding foreign exchange rates, the broader macroeconomic environment, and other external factors. Based on our year-to-day performance and expectations for the fourth quarter, we are raising the midpoint and tightening the range of our operational

Passages & reports (1)
  • what we know today regarding foreign exchange rates, the broader macroeconomic environment…

Speaker 1

sales guidance.

Passages & reports (1)
  • sales guidance.

Speaker 2

We

Passages & reports (1)
  • We

Speaker 1

now expect full year operational sales growth in the range of six point seven percent to seven point one percent, which represents operational sales of one hundred point seven billion at the midpoint or growth of six point nine percent. We do not speculate on future currency

Passages & reports (1)
  • now expect full year operational sales growth in the range of six point seven percent to s…

Speaker 2

movements. As of last week, the Euro spot rate to the US dollar was 1.12. However, the average

Passages & reports (1)
  • movements. As of last week, the Euro spot rate to the US dollar was 1.12. However, the ave…

Speaker 1

rate for the fiscal year stands at 1.15. Based on that average rate, we estimate reported sales growth of 7.2% to 7.6%, with a midpoint of $101.2 billion or 7.4%. Assuming the current spot rate holds into next year, you could expect currency to be a headwind. Turning now to other items of the PL. Regarding operating margin, we now expect a decline

Passages & reports (2)
  • rate for the fiscal year stands at 1.15. Based on that average rate, we estimate reported …
  • expect currency to be a headwind. Turning now to other items of the PL. Regarding operatin…

Speaker 2

of approximately 60 basis

Passages & reports (1)
  • of approximately 60 basis

Speaker 1

points. This is an improvement from the 75 basis points decline reflected in our updated July guidance that included the impact of the Firefly Bio and Sale Biomedicines transactions, which had an unfavorable impact of 150 basis points. Absent those

Passages & reports (1)
  • points. This is an improvement from the 75 basis points decline reflected in our updated J…

Speaker 2

deals, we

Passages & reports (1)
  • deals, we

Speaker 1

continue to deliver base margin improvement.

Passages & reports (1)
  • continue to deliver base margin improvement.

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 2

a reminder, our pre-tax

Passages & reports (1)
  • a reminder, our pre-tax

Speaker 1

adjusted operating margin outlook also reflects the costs associated with the 53rd week of operations and our previously announced

Passages & reports (1)
  • adjusted operating margin outlook also reflects the costs associated with the 53rd week of…

Speaker 2

agreement with the U.S. government to improve access to medicines. For net interest expense, we are lowering our guidance to $150 million to $200 million. We are also tightening the range of our effective tax rate guidance. Based on our year-to-date results, we now expect a full year effective tax rate of 17.0% to 17.5%. Given those updates, we now expect

Passages & reports (2)
  • agreement with the U.S. government to improve access to medicines. For net interest expens…
  • to 17.5%. Given those updates, we now expect

Speaker 1

adjusted operational earnings per share ?in the range of ten dollars and ninety-five cents to eleven dollars and five cents or two percent at the midpoint. We expect reported adjusted earnings per share ?of eleven dollars and five cents to eleven dollars and fifteen cents, with a midpoint of eleven dollars and ten cents or growth of two point nine percent. Excluding the impact of Firefly Bio and Sale Biomedicines transactions of sixty-four cents, reported EPS growth would approach 9%.

Passages & reports (5)
  • adjusted operational earnings per share
  • in
  • the range of ten dollars and ninety-five cents to eleven dollars and five cents or two per…
  • of
  • eleven dollars and five cents to eleven dollars and fifteen cents, with a midpoint of elev…

Speaker unclear

?As

Passages & reports (1)
  • As

Speaker 1

a reminder, for your 2027 modeling, we expect Firefly Bio and Sale Biomedicines to have a combined elutive impact of $1.36 per share on a full-year adjusted earnings per share next ?year. We will provide more details on our 2027 outlook later this year at our Enterprise Business Review. ?Let me now highlight several upcoming developments that reinforce our growth outlook and performance for the remainder of the year.

In oncology, we expect several important data readouts in the fourth quarter. These include data for Pacritamig, a first-in-class bi-specific antibody in patients with advanced prostate cancer who have progressed
after multiple lines of therapy. We also expect data for JNJ 6143, an investigational first-in-class once-daily oral therapy for metastatic castration-resistant prostate cancer. We continue to see strong adoption for Alexo with year to date sales of approximately $200 million and expect to build on that momentum with a data readout in high risk non muscle invasive bladder cancer later this year.

We also expect U.S. approval of Ribovant FASPRO in advanced head and neck cancer. In immunology, as Joaquin referenced earlier, Icotite is off to a strong start, and we look forward to
presenting data in sodiatic arthritis later this ?year. In MedTech, we expect U.S. approval of VariPulse Pro in the fourth quarter, further complementing last week's approval in Japan. In heart recovery, we are taking corrective action to improve ABiomed's performance.

We continue to invest in clinical evidence and expect results from the HRPCI Protect 4
trial in 2027. The trial will have 1,252 patients, four times more than the CHIP BSIS 3 study. This large-scale study will evaluate the safety and efficacy of Abiomed's impella CP pump during high-risk percutaneous coronary intervention. In surgery, we are focused on commercializing Ottawa following its recent FDA de novo authorization.

We expect adoption and revenue contribution to build over time with the goal of establishing OTABA as a significant pillar of our surgery portfolio by the end of the decade. Regarding orthopedics, we remain on track for the planned
separation of the Pew Synthes by mid-2027. ?I am really proud of the team working to evaluate all separation vehicles and all options are better positioned today than when we announced our intentions with this business.

Given the way DePew Synthes is performing
?and the momentum the Malnowana and his team are generating, we are leaning towards a spin as being the best option to create long-term value for Johnson ⁇ Johnson shareholders. That has always been our base plan and we are confident that it can be successfully executed. We will provide additional updates as appropriate and when there is more information to share.

Finally, I am really looking forward to and hope you join us for the Enterprise Business Review on December 8th. At that event, we will provide additional perspective on our 2027 outlook and the key drivers that reinforce our conviction in achieving double digit growth by the end
of the decade. Perhaps more importantly, we will highlight our earlier stage pipeline and how it represents the next wave of growth into the next decade.

Attendees will also have the opportunity to experience firsthand some of our latest innovations, such as Ottawa. 2026 is on track for another successful year,
exceeding expectations set at the beginning of the year. ?We look forward to closing out 2026 strong and setting up 2027 for continued success. Thank you to our colleagues whose dedication and commitment continue to advance innovation, improve patient outcomes, and create long term value for shareholders.

With that,
?we are ready to answer your questions. Kevin, can you please open the call for QA?

Passages & reports (24)
  • a reminder, for your 2027 modeling, we expect Firefly Bio and Sale Biomedicines to have a …
  • year.
  • We will provide more details on our 2027 outlook later this year at our Enterprise Busines…
  • Let
  • me now highlight several upcoming developments that reinforce our growth outlook and perfo…
  • after multiple lines of therapy. We also expect data for JNJ 6143, an investigational firs…
  • and expect to build on that momentum with a data readout in high risk non muscle invasive …
  • presenting data in sodiatic arthritis later this
  • year. In
  • MedTech, we expect U.S. approval of VariPulse Pro in the fourth quarter, further complemen…
  • trial in 2027. The trial will have 1,252 patients, four times more than the CHIP BSIS 3 st…
  • we are focused on commercializing Ottawa following its recent FDA de novo authorization. W…
  • separation of the Pew Synthes by mid-2027.
  • I
  • am really proud of the team working to evaluate all separation vehicles and all options ar…
  • and
  • the momentum the Malnowana and his team are generating, we are leaning towards a spin as b…
  • when there is more information to share. Finally, I am really looking forward to and hope …
  • of the decade. Perhaps more importantly, we will highlight our earlier stage pipeline and …
  • exceeding expectations set at the beginning of the year.
  • We
  • look forward to closing out 2026 strong and setting up 2027 for continued success. Thank y…
  • we
  • are ready to answer your questions. Kevin, can you please open the call for QA?

Speaker 0

Certainly. We'll now be conducting a question and answer session. Ladies and gentlemen, if you'd like to ask a question at this time, please press star then one on your telephone keypad. If you'd like to withdraw your question, please press star then two. We ask you, please limit yourselves to one question only. Our

Passages & reports (1)
  • Certainly. We'll now be conducting a question and answer session. Ladies and gentlemen, if…

Questions & answers

Speaker 0

first question today is coming from Assad Hader from Goldman Sachs.

Passages & reports (1)
  • first question today is coming from Assad Hader from Goldman Sachs.

Speaker 3

Unverified voice label

Great. ?Thanks for taking the question and congrats on all the progress. Just one point of clarification. On the double-digit growth by the end of the decade, the vocabulary in the press release references the progress in the underlying business quote together with strategic investments. Just want to be clear that that refers to internal investments and not MA. That's a question we're getting this morning.

And then Joe, on your comments that you aren't satisfied with the met with MedTech performance and are taking action to strengthen that growth, is the implication there that you are now you now feel more urgency to add to higher growth areas via MA and
MedTech? or do you think that you have the product portfolio today to drive the improved performance you're looking for?

Thank

Passages & reports (5)
  • Great.
  • Thanks
  • for taking the question and congrats on all the progress. Just one point of clarification.…
  • not MA. That's a question we're getting this morning. And then Joe, on your comments that …
  • MedTech? or do you think that you have the product portfolio today to drive the improved p…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Yeah, Asad, uh thank you for your questions. Uh on the the first uh aspect that that is correct. Your interpretation of that being internal strategic investments is what will propel us to uh double digit growth by the end of this decade ?uh in the coming years with increasing performance. Um ?so so that's the is the correct interpretation. It does not assume any inorganic additions uh at this moment in time.

Uh We always are on the lookout for strategic drivers that could complement our business, that uh makes sense to be in our hands versus where the asset would currently reside, but

Passages & reports (5)
  • Yeah, Asad, uh thank you for your questions. Uh on the the first uh aspect that that is co…
  • uh
  • in the coming years with increasing performance. Um
  • so
  • so that's the is the correct interpretation. It does not assume any inorganic additions uh…

Speaker 2

also creates value for the risk we're bearing on behalf

Passages & reports (1)
  • also creates value for the risk we're bearing on behalf

Speaker 1

of shareholders. Um with respect to the urgency, it's it's an urgency to fix what we currently have. We like the portfolio and the construct that currently exists with the three focus areas of vision care uh of surgery as well as cardiovascular. I think you're very familiar, and maybe I'll even hand it over to Tim to talk about some of the things we're doing in heart recovery specifically to address that.

Um what I would say is now a stable business, but we want to catalyze back to double digit growth. Uh we're very excited at what's on the horizon for surgery with the addition of Ottawa over
time. That will be a significant contributor to growth by the end of the decade. Uh and then as I mentioned earlier, vision seems to be uh functioning well both on the surgery side as well as the contact lens side where we are the market leader.

But Tim, maybe you want to offer a
comment or two around uh Abiomed? Sure, Joe. So Asad ultimately Abiomed remained, you know, a temporary headwind as you saw in Q through, but our conviction in the long term opportunity has never has not changed at all. You know, the slowdown we're seeing continues to be ?the same issue we highlighted in the in the quarter before, which is this study outside of the US focused on high risk PCI.

And importantly, we do not view these challenges as structural in nature uh and and ones that will drive a long term impact on the business. We're not seeing any changes in
the patient need, nor to reimbursement access or any meaningful competitive pressures. We also have highlighted some questions we have around the study as to whether best practice were practices were used in the study, and so our focus today is really on education and advancing the clinical evidence based to show the incredible impact that Impella has in both saving and improving lives.

And so we believe it's a short term headwind. It's important to recognize that in any emerging area of science there's always going to be debate and discussion, and our responsibility is to continue to advance the evidence base to support what's in the best interest
of patients. And in the case of Abia Mat AbiaMet, we're doing exactly that. And so a short term headwind, but we are very confident this is going to be a strong platform for growth for Johnson and Johnson for the for the future.

Thank

Passages & reports (9)
  • of shareholders. Um with respect to the urgency, it's it's an urgency to fix what we curre…
  • to Tim to talk about some of the things we're doing in heart recovery specifically to addr…
  • time. That will be a significant contributor to growth by the end of the decade. Uh and th…
  • comment or two around uh Abiomed? Sure, Joe. So Asad ultimately Abiomed remained, you know…
  • the
  • same issue we highlighted in the in the quarter before, which is this study outside of the…
  • the patient need, nor to reimbursement access or any meaningful competitive pressures. We …
  • that Impella has in both saving and improving lives. And so we believe it's a short term h…
  • of patients. And in the case of Abia Mat AbiaMet, we're doing exactly that. And so a short…

Speaker unclear

?you. Thank

Passages & reports (1)
  • you. Thank

Speaker 0

you. Next question today is somewhere from Larry Beagleson from Wells Fargo.

Passages & reports (1)
  • you. Next question today is somewhere from Larry Beagleson from Wells Fargo.

Speaker 4

Unverified voice label

the question.

Passages & reports (1)
  • the question.

Speaker unclear

?Joe, I wanted to ask about

Passages & reports (1)
  • Joe, I wanted to ask about

Speaker 3

the twenty twenty-seven

Passages & reports (1)
  • the twenty twenty-seven

Speaker 4

comments you made um at Deutsche Bank. On the top line, you said you expect reported sales growth to be similar to 2026 after adjusting a hundred basis points for the extra week in both years, uh which I think would mean about five point four percent reported growth next year. And on EPS, how how should we think about your ability to grow earnings, excluding IP R and D, and just remind us of how much ?the Firefly and Sale uh dilution is is IP R and D this year and next year.

Thank

Passages & reports (4)
  • comments you made um at Deutsche Bank. On the top line, you said you expect reported sales…
  • how should we think about your ability to grow earnings, excluding IP R and D, and just re…
  • the
  • Firefly and Sale uh dilution is is IP R and D this year and next year. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Um so for this year the IPR and D dilution is sixty-four cents, and for next year the combination of those deals is a dollar thirty six. Um and uh the way I would think about that, Larry, and you you've covered us long enough where you know ?that typically our income growth or EPS growth will be a little bit better than

Passages & reports (3)
  • Um so for this year the IPR and D dilution is sixty-four cents, and for next year the comb…
  • that
  • typically our income growth or EPS growth will be a little bit better than

Speaker 2

our

Passages & reports (1)
  • our

Speaker 1

sales growth.

Passages & reports (1)
  • sales growth.

Speaker 2

That's how you can think about that next year after adjusting for the dollar thirty six uh adjustment. So we'll continue

Passages & reports (1)
  • That's how you can think about that next year after adjusting for the dollar thirty six uh…

Speaker 1

to look at margin improvement as part of the orthopedic separation, looking more holistically at our business, some of the advances we're getting with technology and getting us more efficient across all parts of our business. But that's probably a good way to kind of frame in your thinking now for 2027. But we'll be a little bit more explicit on December 8th at our investor day, where we'll outline specifically kind of the components to that and then even probably provide a pro forma with respect to the orthopedic separation should that occur at some point next year as well as a longer term outlook.

Passages & reports (2)
  • to look at margin improvement as part of the orthopedic separation, looking more holistica…
  • a little bit more explicit on December 8th at our investor day, where we'll outline specif…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Next question is coming from Chris Schott from JP Morgan Chaser. Why is that

Passages & reports (1)
  • you. Next question is coming from Chris Schott from JP Morgan Chaser. Why is that

Speaker unclear

?live? Uh

Passages & reports (1)
  • live? Uh

Speaker 4

great uh thanks so much. Um just wanted ?to uh touch base

Passages & reports (3)
  • great uh thanks so much. Um just wanted
  • to uh
  • touch base

Speaker unclear

?on ICOTID. So uh just a two part question here. First can you just

Passages & reports (1)
  • on ICOTID. So uh just a two part question here. First can you just

Speaker 5

Unverified voice label

give us an update in terms of what you're seeing in terms of patient uptake as we think about new to biologic versus oral switches versus injectable switches. And then bigger picture for the drug. Uh you're talking about this as a ten billion dollar plus asset. But when you think about this very strong launch we've seen so far in psoriasis, ?we've got a number of additional indications pending.

I guess how do you think about could this be a much larger asset than ten billion as you think about the the peak sales opportunity for for ecotide? Thanks so

Passages & reports (4)
  • give us an update in terms of what you're seeing in terms of patient uptake as we think ab…
  • launch we've seen so far in psoriasis,
  • we've
  • got a number of additional indications pending. I guess how do you think about could this …

Speaker unclear

?much. Great Chris, it's uh Tom,

Passages & reports (1)
  • much. Great Chris, it's uh Tom,

Speaker 1

good to hear from you. Uh first

Passages & reports (1)
  • good to hear from you. Uh first

Speaker 2

I do want to start by recognizing

Passages & reports (1)
  • I do want to start by recognizing

Speaker unclear

?uh Jennifer Talbert and

Passages & reports (1)
  • uh Jennifer Talbert and

Speaker 6

Unverified voice label

thanking her for her tremendous leadership and partnership. Jennifer leaves Innovative Medicine incredibly well positioned as you see from our quarterly earnings with strong momentum, outstanding portfolio and pipeline, and most importantly, a great team. We're fortunate to build on that foundation she established, and I'm excited about what's ahead. And really, what I'm excited about is what you're touching on right now is ICOTID.

We do foresee Icotide to be one of our biggest assets in innovative medicine. Uh and it is off to an incredibly great start, as you highlighted, as Joaquin highlighted on the call this morning. I think getting into some of the launch performance,
uh, you heard it from Joaquin. Already to date, we've seen over 20,000 patients initiated on therapy with over 8,000 prescribers, or nearly 9,000 prescribers, I would say.

So absolutely tracking better than some of most all launches in psoriatic diseases.
?I think early prescribing trends is what you wanted to get at, kind of as we think about exp and we are expanding the systemic marketplace. Approximately sixty percent of the patients are systemic naive, so they haven't received any systemic therapy. And the roughly the 40 remaining 20% are sourced from orals and 20% are sourced from other treatments, most likely biologics, as we dig into the data. ?

So
I can say, as you're seeing with regards to the launch performance, earlier a bit expansion of the marketplace, and absolutely an opportunity to continue to drive that. Highlighted as well, as Joaquin highlighted earlier, I think it's important to point out we do have broad commercial access now and preferred access in place on all national commercial plans or are actively engaged to expand that to the Medicaid Medicare population.

So I would say we're fairly very uh excited about the launch to date, uh as equally as excited about the future. And we do foresee this to be
?you know one of our largest assets as I pointed out. We're excited about the upcoming data readouts, both with a PSA and phase three data as well as the head to head stellar data for Ascend that we should be releasing in the coming months.

And as we look to expand beyond that, and we'll
get more get into more of this at the EBR and IBD uh and expansions into UC and C D, ?uh, expecting similar results with regards to launch performance as we go into those other indications.

Passages & reports (14)
  • thanking her for her tremendous leadership and partnership. Jennifer leaves Innovative Med…
  • excited about is what you're touching on right now is ICOTID. We do foresee Icotide to be …
  • uh, you heard it from Joaquin. Already to date, we've seen over 20,000 patients initiated …
  • I
  • think early prescribing trends is what you wanted to get at, kind of as we think about exp…
  • sourced from other treatments, most likely biologics, as we dig into the data.
  • So
  • I can say, as you're seeing with regards to the launch performance, earlier a bit expansio…
  • all national commercial plans or are actively engaged to expand that to the Medicaid Medic…
  • you
  • know one of our largest assets as I pointed out. We're excited about the upcoming data rea…
  • get more get into more of this at the EBR and IBD uh and expansions into UC and C D,
  • uh,
  • expecting similar results with regards to launch performance as we go into those other ind…

Speaker 0

Thank you. Next question is coming from Joanne Wood from City. Your line is now live.

Passages & reports (1)
  • Thank you. Next question is coming from Joanne Wood from City. Your line is now live.

Speaker 7

Unverified voice label

Uh good morning, and thank you for taking the question. Um I want to focus a little bit on med tech here. When you use the phrase underlying fundamentals and med tech are solid. Um I want to confirm that you're thinking about all the good stuff, the patient volumes, the CAPEX spending from the hospitals, and then what you're seeing in terms of just general flows.

And then as a sister question to that, how do you or what do you think needs to be done to improve the J and J franchise? Thank

Passages & reports (2)
  • Uh good morning, and thank you for taking the question. Um I want to focus a little bit on…
  • hospitals, and then what you're seeing in terms of just general flows. And then as a siste…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Joanne,

Passages & reports (1)
  • Joanne,

Speaker 1

Tim, thank you very much for the question. Let me start by really putting the overall med tech Q three results uh in context for you and and all on the call. And to be clear, our performance is below the standard we have set internally and below the expectations we previously communicated to investors. Simply put, we can uh do better and we absolutely will.

And right now we are focused solely on the actions needed to deliver stronger results in the fourth quarter and beyond.
?And that said, when to your question, you know, when we break down our results, you will see that the pressure was primarily concentrated actually in two very distinct areas. Firstly, our performance outside of

Passages & reports (4)
  • Tim, thank you very much for the question. Let me start by really putting the overall med …
  • Simply put, we can uh do better and we absolutely will. And right now we are focused solel…
  • And
  • that said, when to your question, you know, when we break down our results, you will see t…

Speaker 2

the US,

Passages & reports (1)
  • the US,

Speaker 1

secondly,

Passages & reports (1)
  • secondly,

Speaker 3

Abiomed globally, ?which we were already touched ?on. And to put it in perspective, growth in the US, which as you know is the most important market, was in fact robust in the quarter and accelerated to almost five percent. Our performance outside of the US was a challenge, and it

Passages & reports (5)
  • Abiomed globally,
  • which we were already
  • touched
  • on.
  • And to put it in perspective, growth in the US, which as you know is the most important ma…

Speaker 1

reflected a combination ?of mostly known headwinds, ?which we have discussed previously. For example, in surgery, ?the expected impact of the transformation program

Passages & reports (7)
  • reflected a combination
  • of
  • mostly known headwinds,
  • which we have discussed
  • previously. For example, in surgery,
  • the expected
  • impact of the transformation program

Speaker 3

and ?the ongoing expansion of volume based

Passages & reports (3)
  • and
  • the
  • ongoing expansion of volume based

Speaker 1

procurement in ?China. And in electrophysiology, competitive intensity, especially in Asia Pacific, which is a region that you know is still relatively early in the adoption of PFA. We did introduce a new headwind, which is really the incremental pressure that we're seeing on the business due to the conflict in the Middle East. But when you actually step back and you look deeper into these results, we're seeing several encouraging indicators which give us confidence in a stronger Q4 and outlook beyond that.

For example, in electrophysiology in markets like Europe, where we've already launched VariPulse Pro, which by the way is a faster and easier to use catheter, we're back to
double digit growth. And we will launch VariPulse Pro in Japan shortly after receiving regulatory approval last week. You can also anticipate a U.S. launch by the end of this year. ?I think at AbiaMed we've already touched on the study in IRISPCI, a study where we actually believe that the m methodology employed did not follow well-established practices, an issue which we're addressing through education.

We think we're going to get through that because the evidence base is so solid, especially in areas like AMI cardiogenic
shock, and we're still seeing tremendous performance of 5.5. We did, by the way, already see some improvement sequentially throughout the quarter, and we do believe that that business will be back to growth ?in short order. Now, while Q3 for MedTech was not a strong quarter, this should not distort the whole picture.

As mentioned, the issues are primarily concentrated in the two areas I mentioned. It's also worth reinforcing to your question that the underlying procedure environment remains stable across our key markets. I know there's been a lot of
debate about that. Our job now is to make sure that we convert that demand into more consistent performance. And so we remain remain confident in the combination of the momentum we're seeing in the US and the moderation of these near term headwinds, which will support improved performance in Q four while positioning us for stronger

Passages & reports (12)
  • procurement in
  • China.
  • And in electrophysiology, competitive intensity, especially in Asia Pacific, which is a re…
  • step back and you look deeper into these results, we're seeing several encouraging indicat…
  • double digit growth. And we will launch VariPulse Pro in Japan shortly after receiving reg…
  • I
  • think at AbiaMed we've already touched on the study in IRISPCI, a study where we actually …
  • shock, and we're still seeing tremendous performance of 5.5. We did, by the way, already s…
  • in short order.
  • Now, while Q3 for MedTech was not a strong quarter, this should not distort the whole pict…
  • debate about that. Our job now is to make sure that we convert that demand into more consi…
  • for stronger

Speaker 3

performances in twenty twenty seven and beyond. And as you've already heard from Joaquin and Joe, we'll share more detail around what that looks like for twenty seven and beyond, specifically with a focus on new innovations like Ottawa when we come together on December eighth. Thank

Passages & reports (1)
  • performances in twenty twenty seven and beyond. And as you've already heard from Joaquin a…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 0

Next question today is coming from Jason Grobery from Bank of America. Your mind is now

Passages & reports (1)
  • Next question today is coming from Jason Grobery from Bank of America. Your mind is now

Speaker unclear

?live.

Passages & reports (1)
  • live.

Speaker 0

Hello this

Passages & reports (1)
  • Hello this

Speaker unclear

?is Richard Wagner for Jason. I had a question regarding the

Passages & reports (1)
  • is Richard Wagner for Jason. I had a question regarding the

Speaker 4

ICOtide psoriasis

Passages & reports (1)
  • ICOtide psoriasis

Speaker unclear

?launch. Are there um lessons that can

Passages & reports (1)
  • launch. Are there um lessons that can

Speaker 1

be learned ?that would be useful when ICOTIDE launches an IBD. Specifically in ?IBD, competitors are developing

Passages & reports (5)
  • be learned
  • that would be
  • useful when ICOTIDE launches an IBD. Specifically in
  • IBD, competitors are
  • developing

Speaker unclear

?high efficacy combination programs and wondering

Passages & reports (1)
  • high efficacy combination programs and wondering

Speaker 6

how that could

Passages & reports (1)
  • how that could

Speaker unclear

?affect

Passages & reports (1)
  • affect

Speaker 4

the efficacy perception by positions of ICOTID. Thank

Passages & reports (1)
  • the efficacy perception by positions of ICOTID. Thank

Speaker unclear

?you. Hi

Passages & reports (1)
  • you. Hi

Speaker 6

Richards, this is Tom uh addressing your question. A couple of things I'd point out and I'd obviously turn it over to uh Sean if he has any further remarks with regards to it. I'll say a couple of things. Um, we absolutely know the space very well, whether to be in psoriasis or IBD, and you can tell by the launch that we had with Trimfhya and IBD, it's off to an incredibly great start.

Uh as you can see
?uh over 70% growth uh year over year uh and heavily penetrated into becoming the actually the fastest growing biologic across all indications, in particular in IBD, new patient starts. So we know the space very well. With that said, I will say there's still significant unmet need in a large amount of patients that are untreated or not treated earlier in the course of their diseases.

And we do see that to be a great opportunity
?for not only market expansion as we're seeing in psoriatic disease or psoriasis with icotide, uh, but the profile of the product fits beautifully in that spot, I would say. And uh you know, obviously the data will depend on how we look at it and the positioning once it becomes on the marketplace. But uh I will tell you we'll have early access as one of the other keys and we'll see rapid uptake once we get to the data results.

John? Yeah, maybe uh just to build on that a little bit, the um I think the reason that we've had such a great start in psoriasis is because
of that trifecta biologics like efficacy, uh coupled with placebo like safety, combined with the convenience of a once a day pill. And we think that'll play very well across all indications, including IBD, whereas Tom referenced, still a large percentage of patients are not on an advanced therapy.

Um, you know, the data in our phase two study were quite encouraging and look like Icotite can deliver on par with the current monotherapies. Of course, we're very aware that some patients need something more, that they need a combination therapy, and that's why we're developing
4804, which uh pairs our gosilcumab, our IL-23 inhibitor, with ?uh galimab, our TNF inhibitor, ?and that is in a phase three studies now after really compelling phase two data that show that in that refractory population that have failed two or more prior advanced therapies, this really uh delivers superior efficacy to the monotherapy. ?

So
we're uh actively pursuing that for those patients where a monotherapy is not enough and could see then um you know that opportunity to to migrate patients if needed beyond the monotherapies to the dual therapies with our coantibody 4804.

Passages & reports (17)
  • Richards, this is Tom uh addressing your question. A couple of things I'd point out and I'…
  • and you can tell by the launch that we had with Trimfhya and IBD, it's off to an incredibl…
  • uh
  • over 70% growth uh year over year uh and heavily penetrated into becoming the actually the…
  • untreated or not treated earlier in the course of their diseases. And we do see that to be…
  • for
  • not only market expansion as we're seeing in psoriatic disease or psoriasis with icotide, …
  • I will tell you we'll have early access as one of the other keys and we'll see rapid uptak…
  • of that trifecta biologics like efficacy, uh coupled with placebo like safety, combined wi…
  • advanced therapy. Um, you know, the data in our phase two study were quite encouraging and…
  • 4804, which uh pairs our gosilcumab, our IL-23 inhibitor, with
  • uh
  • galimab, our TNF inhibitor,
  • and
  • that is in a phase three studies now after really compelling phase two data that show that…
  • So
  • we're uh actively pursuing that for those patients where a monotherapy is not enough and c…

Speaker 0

Thank you. Our next question is coming from Vomal DeBlanc from Gulgenheim Securities. Your line is now

Passages & reports (1)
  • Thank you. Our next question is coming from Vomal DeBlanc from Gulgenheim Securities. Your…

Speaker unclear

?live.

Passages & reports (1)
  • live.

Speaker 3

Great. Thanks for uh taking

Passages & reports (1)
  • Great. Thanks for uh taking

Speaker unclear

?the question. Maybe one just follow-up

Passages & reports (1)
  • the question. Maybe one just follow-up

Speaker 1

and then one actual question. Following

Passages & reports (1)
  • and then one actual question. Following

Speaker unclear

?up on the ICOTID, appreciate the comments you've made

Passages & reports (1)
  • up on the ICOTID, appreciate the comments you've made

Speaker 1

so far. Just curious if

Passages & reports (1)
  • so far. Just curious if

Speaker unclear

?you would be willing

Passages & reports (1)
  • you would be willing

Speaker 4

to provide any commentary around the actual net sales in the quarter or on how it compares to where consensus was. We're just getting some questions from investors on that specifically.

Passages & reports (1)
  • to provide any commentary around the actual net sales in the quarter or on how it compares…

Speaker unclear

?And

Passages & reports (1)
  • And

Speaker 1

then my other ?question is just around NLXO. So appreciate

Passages & reports (3)
  • then my other
  • question is just
  • around NLXO. So appreciate

Speaker 4

the comments there you made around the

Passages & reports (1)
  • the comments there you made around the

Speaker 1

sales so far. ?I'm wondering if you can just quantify, I know you have the data coming up later this year as ?well. Uh how you see the market opportunity for that ?expanding based on the current ?indication and then

Passages & reports (9)
  • sales so far.
  • I'm
  • wondering if you can just quantify, I know you have the data coming up later this year as
  • well.
  • Uh how you see the market opportunity for that
  • expanding based on the
  • current
  • indication
  • and then

Speaker 4

what sort of the Sunrise

Passages & reports (1)
  • what sort of the Sunrise

Speaker 3

5

Passages & reports (1)
  • 5

Speaker unclear

?data, what what the size

Passages & reports (1)
  • data, what what the size

Speaker 4

of that ?opportunity is relative to what

Passages & reports (3)
  • of that
  • opportunity is relative to
  • what

Speaker unclear

?you have currently. Thank you. Yeah,

Passages & reports (1)
  • you have currently. Thank you. Yeah,

Speaker 2

uh obviously we

Passages & reports (1)
  • uh obviously we

Speaker unclear

?haven't disclosed any sales for

Passages & reports (1)
  • haven't disclosed any sales for

Speaker 6

ICOTID, but I'm confident

Passages & reports (1)
  • ICOTID, but I'm confident

Speaker unclear

?we're going to be doing that next year, uh just

Passages & reports (1)
  • we're going to be doing that next year, uh just

Speaker 6

based on ?the momentum and the progress that we're seeing

Passages & reports (3)
  • based on
  • the
  • momentum and the progress that we're seeing

Speaker unclear

?with

Passages & reports (1)
  • with

Speaker 3

the launch

Passages & reports (1)
  • the launch

Speaker unclear

?of Icotide. Uh

Passages & reports (1)
  • of Icotide. Uh

Speaker 6

turning over to Nlexo, also another ?exciting product that we have or even ?a platform as ?we think about TAR210 as well and the opportunity that exists for us. We're off to an incredibly great start. Joe disclosed that we're nearly 200 million in net trade sales for a year to date. And quite honestly we haven't reported quarterly sales but I could say that Q3 was north of ninety million dollars.

So we're
seeing great sequential growth. This quarter we saw new patient inserts grow 45% versus the previous quarter. And I wanted to point out that this is in a population in non muscle invasive bladder cancer high risk with carcinogenum in situ. It represents roughly 4,000 patients ?in totality. So relatively small in nature. And we're still seeing one in three patients being put on an LEXO in this patient population.

You touch on Sunrise 5, which is a broader patient population, roughly 15,000 patients, and what we call Sunrise 3, which is the BCG naive population, roughly
?50,000. This ?is where we absolutely see a greater opportunity ?for us to live into the number of five billion plus uh for the

Passages & reports (16)
  • turning over to Nlexo, also another
  • exciting product that
  • we have or even
  • a platform
  • as
  • we think about
  • TAR210 as well and the opportunity that exists for us. We're off to an incredibly great st…
  • seeing great sequential growth. This quarter we saw new patient inserts grow 45% versus th…
  • in totality. So
  • relatively small in nature. And we're still seeing one in three patients being put on an L…
  • 50,000.
  • This
  • is where we
  • absolutely see a greater opportunity
  • for us
  • to live into the number of five billion plus uh for the

Speaker unclear

?platform. And I do believe

Passages & reports (1)
  • platform. And I do believe

Speaker 6

uh

Passages & reports (1)
  • uh

Speaker unclear

?we will do just that and

Passages & reports (1)
  • we will do just that and

Speaker 6

above that, uh, given the unmet medical need, the simplicity of NLEXO delivers and the high response, high durable complete remission rates that we are delivering with Nlexo as we look to expand in the population. Maybe I'll turn it to John to touch on a little bit of the clinical development program. Indeed. Uh the as you know, the approval currently is for the cis type of nonvistell invasive bladder cancer, which spreads laterally.

But the more common is the papillary, and in our so-called Sunrise 1 study, we had a cohort devoted to patients with
papillary cancers where those lesions which project outward from the bladder wall are excised by the urologist, and then in Lexo is applied and one tries to prevent recurrence. And we showed nearly 75% of patients had no recurrence after one year, and that uh over 95% had no progression of their disease.

In other words, they did not progress to more invasive types of disease. So, based on that, the use of NLEXO in that papillary form of the disease, which is the by far the more common, is already in the NC NCCN
guidelines. And the FDA FDA has invited us to submit for a uh expansion of our label into that population.

Passages & reports (5)
  • above that, uh, given the unmet medical need, the simplicity of NLEXO delivers and the hig…
  • the as you know, the approval currently is for the cis type of nonvistell invasive bladder…
  • papillary cancers where those lesions which project outward from the bladder wall are exci…
  • and that uh over 95% had no progression of their disease. In other words, they did not pro…
  • guidelines. And the FDA FDA has invited us to submit for a uh expansion of our label into …

Speaker 2

Both uh Icotide and and ILXo uh are going to be together with Riberbank key drivers of our growth acceleration, driving to double digit growth. So they will become one of our largest products, both of

Passages & reports (1)
  • Both uh Icotide and and ILXo uh are going to be together with Riberbank key drivers of our…

Speaker unclear

?them.

Passages & reports (1)
  • them.

Speaker 0

Thank you. Our next question is coming from Michael Yee from UBS Security. Your line is now live.

Passages & reports (1)
  • Thank you. Our next question is coming from Michael Yee from UBS Security. Your line is no…

Speaker 1

Great. Thank

Passages & reports (1)
  • Great. Thank

Speaker unclear

?you for the

Passages & reports (1)
  • you for the

Speaker 4

questions. Maybe two pipeline science questions. On Icotide, obviously you have great data in psoriasis, a little bit lower than biologics, but great data. In IBD, the the UC data was quite strong. And just wondering if you think that would be replicated to biologic like efficacy

Passages & reports (1)
  • questions. Maybe two pipeline science questions. On Icotide, obviously you have great data…

Speaker 1

as an oral. And and that uh that differentiation there due to the release in the gut is a reason for the potentially stronger data in IBD, which could be a bigger

Passages & reports (1)
  • as an oral. And and that uh that differentiation there due to the release in the gut is a …

Speaker 4

driver. Second part question is on Meldexian.

Passages & reports (1)
  • driver. Second part question is on Meldexian.

Speaker 1

I know you

Passages & reports (1)
  • I know you

Speaker 4

share

Passages & reports (1)
  • share

Speaker 1

in uh that partnership, but SSP data is coming up, and I just wanted to check in on your confidence that that should be similar to asyndexian, and that should be a fairly de-risked indication as a factor eleven. Thank

Passages & reports (1)
  • in uh that partnership, but SSP data is coming up, and I just wanted to check in on your c…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker unclear

?But

Passages & reports (1)
  • But

Speaker 6

on icotide and IBD, we get that question all the time, asking might we see even greater efficacy with an oral because of the gut absorption. ?I all I can say is to be determined. We were quite pleased with the phase two data and ulcer colitis. Um I would also say the phase three studies, as we saw with our psoriasis and psoriatic arthritis studies, uh are enrolling briskly.

Uh in the prior studies they enrolled in about a third the
time that it normally takes us to enroll in those indications, reflecting I think the uh real enthusiasm that both uh physicians and patients have for this oral option. So um, you know, that's uh that theory about oral of oral uh absorption and and improved efficacy to be determined by the data.

Um moving to to milvexian, now we remain confident in uh the uh studies underway uh particularly with the secondary stroke because of the asunxian data. As we know in vitro uh milvexian is a more potent
inhibitor of factor 11. Uh we also have been able to have an uh safety margin that allows us to push that dose to ranges that we're confident are quite effective.

So we remain confident uh in the results and expect uh that perhaps
the secondary stroke data will be available even this year. It's event-driven the study. ?Uh the atrial fibrillation, the larger population uh will be next year. It'll be exciting for us if we can prevail in both those indications because about 25% of patients who are candidates for secondary stroke have atrial fibrillation.

That's probably why they had the stroke in the
first place. And so if we can benefit both of those populations, that'll be exciting. We are confident in the atrial fibrillations study as well. There, we were able to push the dose four times higher given our safety margin in the drug and feel from monitoring of the anticoagulation status of the blood with laboratories that uh we're in the right range to benefit patients and prevent thrombosis.

So thank you for the question.
?Yeah I just reinforced what John ?has said there's an absolute need for highly effective

Passages & reports (15)
  • on icotide and IBD, we get that question all the time, asking might we see even greater ef…
  • I
  • all I can say is to be determined. We were quite pleased with the phase two data and ulcer…
  • time that it normally takes us to enroll in those indications, reflecting I think the uh r…
  • determined by the data. Um moving to to milvexian, now we remain confident in uh the uh st…
  • inhibitor of factor 11. Uh we also have been able to have an uh safety margin that allows …
  • the secondary stroke data will be available even this year. It's event-driven the study.
  • Uh
  • the atrial fibrillation, the larger population uh will be next year. It'll be exciting for…
  • first place. And so if we can benefit both of those populations, that'll be exciting. We a…
  • laboratories that uh we're in the right range to benefit patients and prevent thrombosis. …
  • Yeah I just
  • reinforced what John
  • has said there's
  • an absolute need for highly effective

Speaker 3

oral anticoagulation therapy

Passages & reports (1)
  • oral anticoagulation therapy

Speaker unclear

?with a reduced

Passages & reports (1)
  • with a reduced

Speaker 6

bleeding risk. In AFib alone, approximately forty percent of the patients eligible for oral anticoagulants are not receiving oral anticoagulants, typically due to the concerns on potential safety and the bleeding risks associated with the current ODEX.

Passages & reports (1)
  • bleeding risk. In AFib alone, approximately forty percent of the patients eligible for ora…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 0

you. Our next question is coming from Jason Bedford from Raymond James. Reline is now live.

Passages & reports (1)
  • you. Our next question is coming from Jason Bedford from Raymond James. Reline is now live…

Speaker unclear

?Good morning.

Passages & reports (1)
  • Good morning.

Speaker 6

Thanks for taking the question. ?Just uh I wanted to go back to ?the international medtech business. Is there any way to quantify the impact of the dynamics in the Mideast and VBP? And then, Tim, ?uh I wanted to ask about international

Passages & reports (7)
  • Thanks for taking the question.
  • Just uh I
  • wanted to go back to
  • the
  • international medtech business. Is there any way to quantify the impact of the dynamics in…
  • uh
  • I wanted to ask about international

Speaker 1

surgery.

Passages & reports (1)
  • surgery.

Speaker 6

First, just to

Passages & reports (1)
  • First, just to

Speaker 1

confirm your view

Passages & reports (1)
  • confirm your view

Speaker 6

that is that there's been no change to the underlying demand profile internationally. And then second, I think Joe mentioned taking actions internationally uh for for surgery. What

Passages & reports (1)
  • that is that there's been no change to the underlying demand profile internationally. And …

Speaker unclear

?are those actions?

Passages & reports (1)
  • are those actions?

Speaker 1

Thanks. Thank you, Jason. Let me uh let me try to get to ?all of those. Let me start with the the the Middle East and and clearly

Passages & reports (3)
  • Thanks. Thank you, Jason. Let me uh let me try to get to
  • all of
  • those. Let me start with the the the Middle East and and clearly

Speaker unclear

?we've highlighted that as a

Passages & reports (1)
  • we've highlighted that as a

Speaker 1

a

Passages & reports (1)
  • a

Speaker unclear

?new risk that has broadened over time. And really the effect

Passages & reports (1)
  • new risk that has broadened over time. And really the effect

Speaker 1

is ?no longer limited to a handful of markets as we initially thought. We've seen increased disruption,

Passages & reports (3)
  • is
  • no
  • longer limited to a handful of markets as we initially thought. We've seen increased disru…

Speaker unclear

?you know, to ordering patterns, tender timing and hospital spending decisions across a

Passages & reports (1)
  • you know, to ordering patterns, tender timing and hospital spending decisions across a

Speaker 1

wider group ?of countries, unfortunately. And we've

Passages & reports (3)
  • wider group
  • of
  • countries, unfortunately. And we've

Speaker unclear

?also seen

Passages & reports (1)
  • also seen

Speaker 3

governments ?and healthcare systems become more cautious in their spending priorities,

Passages & reports (3)
  • governments
  • and
  • healthcare systems become more cautious in their spending priorities,

Speaker 1

with some funding and procurement decisions taking longer than what we normally would expect.

Passages & reports (1)
  • with some funding and procurement decisions taking longer than what we normally would expe…

Speaker unclear

?That has created a more meaningful impact on purchasing

Passages & reports (1)
  • That has created a more meaningful impact on purchasing

Speaker 3

behavior

Passages & reports (1)
  • behavior

Speaker unclear

?than we

Passages & reports (1)
  • than we

Speaker 1

saw earlier in

Passages & reports (1)
  • saw earlier in

Speaker unclear

?the

Passages & reports (1)
  • the

Speaker 3

year. That said, I think it's important,

Passages & reports (1)
  • year. That said, I think it's important,

Speaker unclear

?you

Passages & reports (1)
  • you

Speaker 1

know,

Passages & reports (1)
  • know,

Speaker 3

that we ?see this really as a short-term factor. I mean, ?the underlying issues have not changed. The clinical need remains intact and we would have we'd expect many of these opportunities to be deferred rather than ?permanently lost. ?So I think that's an important factor as it relates to any form of conflict and certainly ?what we're seeing in the in the Middle East.

You know, on on surgery, as I mentioned, we were actually really excited about the performance of the business in the U.S. Our issue really was outside of the U.S.

Passages & reports (11)
  • that we
  • see this really
  • as a short-term factor. I mean,
  • the
  • underlying issues have not changed. The clinical need remains intact and we would have we'…
  • permanently
  • lost.
  • So
  • I think that's an important factor as it relates to any form of conflict and certainly
  • what
  • we're seeing in the in the Middle East. You know, on on surgery, as I mentioned, we were a…

Speaker 1

and as you know primarily driven by factors we've discussed before, such as

Passages & reports (1)
  • and as you know primarily driven by factors we've discussed before, such as

Speaker unclear

?the transformation program and volume based

Passages & reports (1)
  • the transformation program and volume based

Speaker 1

procurement. And then, of course, ?the incremental pressure that we've just mentioned around the Middle East. I will say that despite those headwinds, you know, we're focused on where we can have an impact, and we have a lot of opportunities.

Passages & reports (3)
  • procurement. And then, of course,
  • the
  • incremental pressure that we've just mentioned around the Middle East. I will say that des…

Speaker unclear

?You know, wound

Passages & reports (1)
  • You know, wound

Speaker 2

closure growth continued to benefit. This is a category ?where we absolutely dominate,

Passages & reports (3)
  • closure growth continued to benefit. This is a category
  • where
  • we absolutely dominate,

Speaker unclear

?and that's that growth has been driven by

Passages & reports (1)
  • and that's that growth has been driven by

Speaker 1

innovation such as StratiFix and Plus Sutures, biosurgery, and other north of billion dollar platform delivered solid growth driven by key brands like Surgiflow, Surgicell, and VistaCeel. And we continue to see good traction with our in the mechanical innovations such as at the Cont 4000 and Dualto. And ?so we are confident that we will see continued growth in the US. And to your question, we will see acceleration in EMEA and return to growth

Passages & reports (3)
  • innovation such as StratiFix and Plus Sutures, biosurgery, and other north of billion doll…
  • so
  • we are confident that we will see continued growth in the US. And to your question, we wil…

Speaker unclear

?overall in the fourth

Passages & reports (1)
  • overall in the fourth

Speaker 3

quarter. ?I do think it's more

Passages & reports (3)
  • quarter.
  • I
  • do think it's more

Speaker 1

also

Passages & reports (1)
  • also

Speaker unclear

?mentioned worth

Passages & reports (1)
  • mentioned worth

Speaker 3

and worth mentioning our confidence in this business going forward. This was the core to how we started Johnson Johnson MedTech, and we are absolutely committed to it for the long term. I'd say the biggest reason for confidence

Passages & reports (1)
  • and worth mentioning our confidence in this business going forward. This was the core to h…

Speaker 1

is the fact ?that we will be entering the surgical robot robotic space

Passages & reports (3)
  • is the fact
  • that we will
  • be entering the surgical robot robotic space

Speaker 3

and you know, combined with our leadership positions across wound closure, biosurgery, and advanced instrumentation, we believe that Ottawa gives ?us an opportunity to participate more fully in one of the most attractive and underpenetrated areas

Passages & reports (3)
  • and you know, combined with our leadership positions across wound closure, biosurgery, and…
  • us
  • an opportunity to participate more fully in one of the most attractive and underpenetrated…

Speaker 1

of surgery. And so, you know, as we continue to execute our portfolio transformation, advance innovation across the existing business, and prepare for the launch of Ottawa, we remain confident in the long term trajectory of the surgery franchise. We do get a lot of questions on Ottawa and rest assured that when you come together for the meeting on December eighth, we will provide perspective on the outlook for that for that for that innovation and further build your confidence in what we believe will be a material contributor to Johnson and Johnson's growth over the long ?term.

Thank you. Thank you Jason. We have time for one last question. question.

Passages & reports (4)
  • of surgery. And so, you know, as we continue to execute our portfolio transformation, adva…
  • together for the meeting on December eighth, we will provide perspective on the outlook fo…
  • term.
  • Thank you. Thank you Jason. We have time for one last question. question.

Speaker 0

Certainly, our final question today is coming from Alex Hammond from Wolf Research. Your line is now live.

Passages & reports (1)
  • Certainly, our final question today is coming from Alex Hammond from Wolf Research. Your l…

Speaker unclear

?Thanks for squeezing me in. So I guess as

Passages & reports (1)
  • Thanks for squeezing me in. So I guess as

Speaker 1

the Cartitude

Passages & reports (1)
  • the Cartitude

Speaker unclear

?5 and 6 trials

Passages & reports (1)
  • 5 and 6 trials

Speaker 6

had advanced and newly diagnosed

Passages & reports (1)
  • had advanced and newly diagnosed

Speaker unclear

?multiple myeloma, how is

Passages & reports (1)
  • multiple myeloma, how is

Speaker 1

JJ preparing to educate

Passages & reports (1)
  • JJ preparing to educate

Speaker 6

physicians and treatment centers for the potential shift to use in earth earlier into the treatment journey? And I guess how should investors think about the potential to capture share from these existing frontline regimens? Thank

Passages & reports (1)
  • physicians and treatment centers for the potential shift to use in earth earlier into the …

Speaker unclear

?you. Hi,

Passages & reports (1)
  • you. Hi,

Speaker 2

Alex,

Passages & reports (1)
  • Alex,

Speaker unclear

?it's Tom. Thanks for the question. I think first and foremost, yes, we're

Passages & reports (1)
  • it's Tom. Thanks for the question. I think first and foremost, yes, we're

Speaker 6

anxiously awaiting for those trials to read out. I would say we're already doing that right now with Cartitude 4 across the globe.

Passages & reports (1)
  • anxiously awaiting for those trials to read out. I would say we're already doing that righ…

Speaker 6

to the product and excitement about it, predominantly due to the unmatched overall survival as early as line two of therapy that we see in versus standard of care. So we're already educating uh healthcare providers on the product and how they can use utilize it earlier. Uh some of the education that is centered around is appropriate patient selection and the earlier the better, as well as proper bridging, getting the patients to the highest level of MRD negativity uh to be effectively treated with carvicty.

Maybe just
?to remind on top of that that uh at the recent Myloma ?meetings we showed five-year follow-up data from

Passages & reports (6)
  • to the product and excitement about it, predominantly due to the unmatched overall surviva…
  • around is appropriate patient selection and the earlier the better, as well as proper brid…
  • to
  • remind on top of that that uh at the recent Myloma
  • meetings we
  • showed five-year follow-up data from

Speaker 1

the Cartitudes

Passages & reports (1)
  • the Cartitudes

Speaker 6

2

Passages & reports (1)
  • 2

Speaker 1

study that's in second line

Passages & reports (1)
  • study that's in second line

Speaker 6

showing that about half of those patients enjoyed uh complete uh remission out to five years with no further treatment. So a one and done in five years of uh continued disease free survival. So uh very exciting data.

Passages & reports (1)
  • showing that about half of those patients enjoyed uh complete uh remission out to five yea…

Speaker 2

Great.

Passages & reports (1)
  • Great.

Speaker unclear

?Thank you,

Passages & reports (1)
  • Thank you,

Speaker 1

John, And thank you, Alex, ?for the

Passages & reports (3)
  • John, And thank you, Alex,
  • for
  • the

Speaker 2

question. And thanks to everyone for your questions and continued interest in our company.

Passages & reports (1)
  • question. And thanks to everyone for your questions and continued interest in our company.

Speaker unclear

?I

Passages & reports (1)
  • I

Speaker 1

will now turn the call over to Joaquin for some brief closing remarks. Thank you for your questions and your

Passages & reports (1)
  • will now turn the call over to Joaquin for some brief closing remarks. Thank you for your …

Speaker 2

engagements in today's call. As you can see, we can s we continue to build momentum. Growth improves sequentially in the third quarter, and we expect further acceleration in 2027 with a clear path to double digit growth by the end of the decade. In innovative medicine, growth will come from both our existing portfolio, including Darsalex and Trenfaia, and newer products such as Icotite, Riberban and Ilexo, as they begin to contribute more meaningfully.

We see similar opportunities in MedTech, the potential from our cardiovascular launches, including next generation PFA
and IBL catheters. Additional data supporting IMPELA and Ottawa in robotic surgery are not yet fully reflected in our growth. Taken together, these drivers position Johnson Johnson as one of the cleanest growth stories in healthcare. We'll provide more details about our portfolio and late stage pipeline at our enterprise business review later in December.

Thank you very much and enjoy the rest of your day.

Passages & reports (4)
  • engagements in today's call. As you can see, we can s we continue to build momentum. Growt…
  • both our existing portfolio, including Darsalex and Trenfaia, and newer products such as I…
  • and IBL catheters. Additional data supporting IMPELA and Ottawa in robotic surgery are not…
  • portfolio and late stage pipeline at our enterprise business review later in December. Tha…

Speaker 0

This concludes today's Johnson Johnson's third quarter 2026 earnings conference call.

Passages & reports (1)
  • This concludes today's Johnson Johnson's third quarter 2026 earnings conference call.
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

3 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 3. Unassigned words: 395. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T00:50:13.062Z.
Transcript version v1-cbf2aed6167f1e9bf416 · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.